May 15, 2025 – Novo Holdings is pleased to announce the appointments of Jun Sung Kim, Lars Green, N.P. “Narv” Narvekar and Torsten Sløk to its Board of Directors, effective May 14, 2025. These distinguished leaders bring a broad range of investment expertise spanning both U.S. and international markets, further strengthening the Board’s global perspectives […]
Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund focused on building innovative companies in areas of high unmet medical need. Following the investment, HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute (BII) to increase […]
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of […]
Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates (“TA”), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites (“the Company”), […]
It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]
